StreetInsider.com News Articles

Form ARS Pelthos Therapeutics For: Dec 31

Tue, 18 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945385.html

Form ARS Pelthos Therapeutics For: Dec 31

Tue, 18 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945385.html

Form DEFA14A Pelthos Therapeutics

Tue, 18 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26945309.html

Form DEFA14A Pelthos Therapeutics

Tue, 18 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26945309.html

Form DEF 14A Pelthos Therapeutics For: Sep 29

Tue, 18 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26945241.html

Form DEF 14A Pelthos Therapeutics For: Sep 29

Tue, 18 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26945241.html

Pelthos Therapeutics (PTHS) PT Lowered to $64 at Oppenheimer

Fri, 14 Aug 2026 08:34:01 -0400

Oppenheimer analyst Jeff Jones lowered the price target on Pelthos Therapeutics (NYSE: PTHS) to $64.00 (from $66.00) while maintaining a Outperform rating.

Form 10-Q Pelthos Therapeutics For: Jun 30

Thu, 13 Aug 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26916414.html

Form 10-Q Pelthos Therapeutics For: Jun 30

Thu, 13 Aug 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26916414.html

Pelthos Therapeutics Inc. (PTHS) Misses Q2 EPS by 611c

Thu, 13 Aug 2026 07:18:04 -0400

Pelthos Therapeutics Inc. (NYSE: PTHS) reported Q2 EPS of ($6.62), $6.11 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $15.6 million.

For earnings history and earnings-related data on Pelthos Therapeutics Inc. (PTHS) click here.

Form 8-K Pelthos Therapeutics For: Aug 13

Thu, 13 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26916389.html

Form 8-K Pelthos Therapeutics For: Aug 13

Thu, 13 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26916389.html

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Form 10-Q/A Pelthos Therapeutics For: Mar 31

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916311.html

Form 10-Q/A Pelthos Therapeutics For: Mar 31

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916311.html

Form 8-K Pelthos Therapeutics For: Aug 12

Thu, 13 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26916253.html

Form 8-K Pelthos Therapeutics For: Aug 12

Thu, 13 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26916253.html

Form PRE 14A Pelthos Therapeutics For: Sep 29

Fri, 07 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26892009.html

Form PRE 14A Pelthos Therapeutics For: Sep 29

Fri, 07 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26892009.html

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Mon, 03 Aug 2026 08:00:00 -0400

DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time.

Details for the conference call can be found below:

Date:	Thursday, August 13, 2026
Time:	8:30 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf.ID:	13761132

Call.Me: Participants can use the dial-in numbers above or

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Mon, 03 Aug 2026 08:00:00 -0400

Details for the conference call can be found below:

Date:	Thursday, August 13, 2026
Time:	8:30 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf.ID:	13761132

Call.Me: Participants can use the dial-in numbers above or

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Mon, 03 Aug 2026 08:00:00 -0400

Details for the conference call can be found below:

Date:	Thursday, August 13, 2026
Time:	8:30 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf.ID:	13761132

Call.Me: Participants can use the dial-in numbers above or